5-HT7 receptor — Drug Target

All drugs that target 5-HT7 receptor — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

5-HT7 receptor antagonist

Phase 3 pipeline (4)

• LY2216684 · Eli Lilly and Company · 5-HT7 receptor antagonist · Psychiatry/Neurology
  LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.
• OPC-34712 · Otsuka Pharmaceutical Development & Commercialization, Inc. · 5-HT7 receptor antagonist · Psychiatry/Neurology
  OPC-34712 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.
• NMRA-335140 · Neumora Therapeutics, Inc. · 5-HT7 receptor antagonist · Psychiatry/Neurology
  NMRA-335140 is a selective serotonin 5-HT7 receptor antagonist designed to modulate mood and emotional processing through central nervous system effects.
• OPC-34712 + ADT · Otsuka Pharmaceutical Development & Commercialization, Inc. · 5-HT7 receptor antagonist · Oncology
  OPC-34712 is a selective serotonin 5-HT7 receptor antagonist combined with androgen deprivation therapy (ADT) to treat prostate cancer.

Phase 2 pipeline (1)

• DFN-15 Dose 1 · Dr. Reddy's Laboratories Limited · 5-HT7 receptor antagonist · Psychiatry/Neurology
  DFN-15 is a selective serotonin 5-HT7 receptor antagonist designed to modulate serotonergic neurotransmission.